top of page

OnQuality announces FDA clearance of IND for OQL011

Shanghai, China—May 24th, 2019. OnQuality Pharmaceuticals Ltd., today announced the U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug Application for OQL011, to proceed into a Phase II clinical trial to evaluate its safety and efficacy in the treatment of hand-foot skin reaction induced by VEGFR inhibitors in cancer patients

About Hand-Foot Skin Reaction (HFSR)

HFSR is a common cutaneous toxicity induced by the multi-tyrosine kinase inhibitors, which are known as targeted oncology therapeutics.

About OnQuality Pharmaceuticals

OnQuality Pharmaceuticals is dedicated to pioneering the discovery and development of mechanism-based therapies that have the potential to improve both quality-of-life and outcomes for cancer patients by managing the dose-limiting toxicities of cancer therapeutics.


bottom of page